News

May 15, 2018January 22, 2019

FDA Grants Priority Review to Tecentriq Combo for First-Line Treatment of Advanced Lung Cancer

News

The U.S. Food and Drug Administration has granted priority review to Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy medications Taxol (paclitaxel) and carboplatin for first-line treatment of metastatic non-squamous non-small ... Read more

May 11, 2018

Canada Approves Imfinzi for Advanced, Inoperable Non-small Cell Lung Cancer

News

Health Canada recently approved Imfinzi (durvalumab) for the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), AstraZeneca Canada announced. The approval is for patients with stage 3 ... Read more

May 9, 2018May 9, 2018

Researchers May Now Predict Which CLL Patients Will Respond to Kymriah CAR T-Cell Therapy, Study Says

News

The absence of a specific T-cell subset may help explain why three in four patients with advanced chronic lymphocytic leukemia (CLL) fail to respond to Kymriah (tisagenlecleucel) — a CAR T-cell ... Read more

May 8, 2018

Study Evaluating VBI-1901 Enrolling Recurrent GBM Patients in Second Dose Group

News

An Independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the Phase 1/2 clinical trial evaluating VBI Vaccines’ VBI-1901 continue to enroll patients with recurrent glioblastoma (GBM) in a ... Read more

May 4, 2018

Advanced Melanoma Patients Seen to Respond to CMP-001, Keytruda Combo in Ongoing Study

News

Intratumoral injection of CMP-001 in combination with Keytruda (pembrolizumab) worked to reduce tumor burden in advanced melanoma patients whose disease failed to respond, or progressed, when treated with PD-1 inhibitors, data ... Read more

May 2, 2018May 2, 2018

EMA to Review Keytruda Combo as First-line Treatment for Advanced NSCLC Patients in EU

News

The European Medicines Agency (EMA) has started the review process for Merck‘s application seeking approval of Keytruda (pembrolizumab) in combination with Alimta (pemetrexed) and platinum chemotherapy as a first-line treatment for patients ... Read more

May 1, 2018

New Combo Treatment for Advanced Solid Tumors is Goal of Partnership

News

CBT Pharmaceuticals and CrystalGenomics announced they are developing a combination therapy — CBT-501 plus CG200745 — with the potential to treat people with various advanced solid cancers. The companies plan to test ... Read more

April 27, 2018April 27, 2018

Once Monthly Opdivo Use Approved in EU for Certain Melanoma, Renal Cell Cancer Patients

News

The European Commission has approved a new dosing schedule for Opdivo (nivolumab), allowing the PD-1 inhibitor to be given every four weeks to patients with advanced melanoma and those with previously treated renal ... Read more

April 25, 2018April 25, 2018

Imfinzi, Tremelimumab Combo Benefits Advanced Urothelial Cancer Patients, Phase 1 Trial Data Show

News

An immunotherapy combining an approved and an investigative treatment — Imfinzi (durvalumab) and tremelimumab — showed potential to reduce tumor activity and prolong survival as a second-line therapy in patients with metastatic ... Read more

April 24, 2018April 24, 2018

CAR T-cell Therapy at Higher Dose Might Treat Advanced Neuroblastoma, Early Trial Results Suggest

News

At higher doses, an immunotherapy approach using chimeric antigen receptor (CAR) T-cells may help to treat advanced neuroblastoma, a rare cancer that mostly affects babies and young children, according to early ... Read more